Retatrutide Hair and Skin Changes: What the Clinical Evidence Shows

What Retatrutide Is and Why Its Weight-Loss Magnitude Matters for Skin and Hair

Retatrutide (LY3437943) is a single peptide that simultaneously activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. That triple mechanism produces substantially greater weight loss than any approved GLP-1 monotherapy. In the Jastreboff et al. Phase 2 trial published in the New England Journal of Medicine, participants receiving 12 mg weekly lost a mean of 24.2% of body weight by week 48, compared with 2.1% in the placebo group 1.

That degree of weight loss is clinically meaningful and medically welcome. It is also the single biggest driver of the hair and skin changes patients ask about.

Why Magnitude Matters More Than the Drug Itself

Hair follicle biology responds to nutritional and metabolic stress, not specifically to GLP-1 receptor activation. Any intervention that produces rapid, large reductions in caloric availability can shift follicles from the anagen (growth) phase into telogen (rest), producing the diffuse shedding pattern known as telogen effluvium 2.

The faster and deeper the deficit, the higher the probability of shedding. Retatrutide's 24.2% mean weight loss at 48 weeks substantially exceeds what semaglutide 2.4 mg achieved in STEP-1 (14.9% at 68 weeks, N=1,961) 3. Patients and prescribers should anticipate proportionally greater hair-related effects with retatrutide than with currently approved agents.

Current Regulatory Status

Retatrutide has not received FDA approval as of mid-2025. Phase 3 trials are ongoing. All clinical data cited here come from the phase 2 publication 1. Prescribing outside a clinical trial setting occurs only through compounding pharmacies under patient-specific prescriptions, and safety monitoring in that context is less rigorous than in a formal trial.

Alopecia Rates Reported in the Phase 2 Trial

Raw Numbers from the Jastreboff et al. Dataset

The phase 2 trial enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related comorbidity and randomized them across seven dose arms of retatrutide (1 mg, 2 mg, 4 mg, 8 mg, 8 mg high-loading, 12 mg, and 12 mg high-loading) and placebo 1.

Alopecia was listed among adverse events. At the 12 mg dose, approximately 9% of participants reported alopecia, compared with a low single-digit percentage at lower doses and near-zero in the placebo arm. The incidence tracked with weight-loss magnitude across dose groups, consistent with a metabolic rather than direct pharmacologic mechanism.

How This Compares With Other GLP-1-Class Agents

Across the STEP program for semaglutide 2.4 mg, alopecia was reported in approximately 3% of participants 3. Tirzepatide's SURMOUNT-1 trial (N=2,539) reported alopecia in 5.7% of participants at the 15 mg dose 4. Retatrutide's 9% figure at 12 mg sits above both, which aligns with its superior weight-loss performance.

The American Academy of Dermatology notes that telogen effluvium following rapid weight loss is "well-documented and self-limiting in the majority of cases," typically resolving within three to six months once caloric intake stabilizes 5.

The Physiology of Telogen Effluvium in Rapid Weight Loss

Follicle Biology Under Caloric Stress

Each hair follicle cycles through anagen (2-7 years of active growth), catagen (2-3 weeks of regression), and telogen (3-4 months of rest before the hair sheds). Under normal nutritional conditions, roughly 85-90% of scalp follicles are in anagen at any moment 2.

A sustained caloric deficit of roughly 500-1,000 kcal/day, which is typical during aggressive GLP-1/GIP/glucagon agonist therapy, can shift 30-50% of follicles into telogen simultaneously. The shedding event appears 6-16 weeks later, when those telogen hairs reach their natural exit point.

Nutritional Cofactors That Amplify Risk

Protein deficiency is the most clinically significant amplifier. Hair is approximately 95% keratin. When dietary protein falls below 0.8 g/kg/day, keratin synthesis is deprioritized in favor of visceral protein maintenance 6.

Retatrutide's profound appetite suppression makes inadequate protein intake likely without deliberate dietary planning. Secondary deficiencies in ferritin (target serum ferritin above 40 ng/mL for hair maintenance), zinc, biotin, and vitamin D compound follicle stress. A 2022 review in the Journal of the American Academy of Dermatology linked low serum ferritin specifically to prolonged telogen effluvium in weight-loss patients 7.

Why Retatrutide May Pose Higher Risk Than Older Agents

Three factors combine to raise risk relative to semaglutide or tirzepatide:

1. Greater absolute weight loss (24.2% vs. 14.9% or 20.9% in phase 3 tirzepatide data)
2. Faster rate of loss, particularly in the first 24 weeks when the glucagon component is most active in driving energy expenditure
3. More severe nausea and vomiting at the 12 mg dose, which reduces dietary intake further beyond the pharmacologic suppression of appetite

The Jastreboff trial reported nausea in 58% and vomiting in 28% of participants at 12 mg 1. Both symptoms directly reduce protein and micronutrient consumption.

Skin Changes Associated With Retatrutide

Skin Laxity After Substantial Fat Loss

Skin laxity after weight loss is primarily a mechanical phenomenon. Adipose tissue provides structural support to the dermis. When fat mass decreases by 20-25% of total body weight, the overlying skin loses that support faster than collagen and elastin can remodel.

Collagen turnover in adult skin takes months to years. The skin may appear loose, particularly around the abdomen, upper arms, thighs, and face, in patients who lose weight rapidly 8. No direct evidence links retatrutide to any adverse effect on collagen synthesis itself. The laxity is a geometric consequence of volume loss, not a drug-specific dermal toxicity.

GLP-1 Receptors in Skin: Potential Protective Signals

GLP-1 receptors are expressed in human keratinocytes and dermal fibroblasts. Preclinical data suggest GLP-1 receptor activation may promote collagen synthesis and reduce dermal inflammation 9. Whether this translates to a clinically meaningful skin-protective effect during retatrutide use is not yet established in humans.

Retatrutide's glucagon receptor activity may separately influence adipokine signaling in the dermis, but no human trials have assessed skin histology as a primary or secondary endpoint 1.

Injection-Site Reactions

The phase 2 trial documented injection-site reactions in a small percentage of participants across all active dose groups 1. These included erythema, mild induration, and pruritus at the subcutaneous injection site. They were generally transient (resolving within 24-48 hours), did not require dose discontinuation, and are consistent with the class effect seen across GLP-1 receptor agonists.

Patients should rotate injection sites weekly, use subcutaneous tissue in the abdomen, thigh, or upper arm, and avoid injecting into areas with active skin changes.

Glycemic-Mediated Skin Improvements

For patients with type 2 diabetes or prediabetes, improved glycemic control from retatrutide may benefit the skin indirectly. Persistent hyperglycemia accelerates advanced glycation end-product (AGE) accumulation in dermal collagen, stiffening the extracellular matrix and impairing wound healing 10. Reductions in HbA1c of 2-3 percentage points, as seen with retatrutide in the phase 2 data, could reduce AGE-mediated dermal damage over months 1.

Monitoring Protocol for Hair and Skin During Retatrutide Therapy

Laboratory Testing

Clinicians prescribing retatrutide (or overseeing its off-label compounded use) should obtain baseline and quarterly reassessment of the following:

• Serum ferritin (target above 40 ng/mL; supplement if below 30 ng/mL)
• Complete blood count to detect iron-deficiency anemia
• Zinc (serum zinc; target above 70 mcg/dL)
• 25-hydroxyvitamin D (target 40-60 ng/mL)
• Total protein and albumin (to gauge overall protein nutritional status)
• Thyroid-stimulating hormone (hypothyroidism independently causes hair loss and must be excluded)

The Endocrine Society's 2023 obesity pharmacotherapy guidelines recommend baseline nutritional labs before initiating any high-efficacy weight-loss agent, given the expected reduction in dietary intake 11.

Protein and Caloric Targets

Patients should consume a minimum of 1.2 g of protein per kilogram of body weight per day, with 1.6 g/kg/day being a defensible upper target during active weight loss 6. For a 100 kg patient, that means 120-160 g of protein daily, distributed across at least three meals to optimize muscle protein synthesis.

Total caloric intake should not fall below 1,200 kcal/day in women or 1,500 kcal/day in men. GLP-1/GIP/glucagon agonists may suppress appetite enough that patients spontaneously eat below these floors; food logs or registered dietitian co-management should catch this early.

Dermatology Referral Triggers

Refer to dermatology if:

• Hair shedding is severe (more than 150-200 hairs per day on a standardized pull test)
• Shedding persists beyond six months after weight stabilization
• Patches of complete hair loss appear (suggesting alopecia areata rather than telogen effluvium)
• Skin laxity is creating functional problems (recurrent intertriginous infections, impaired mobility)
• Injection-site reactions fail to resolve within 72 hours or develop signs of infection

Treatments and Mitigations for Retatrutide-Associated Hair Changes

Evidence-Based Topical Options

Minoxidil 2% or 5% topical solution applied twice daily has evidence supporting acceleration of hair regrowth after telogen effluvium 12. It does not stop the initial shed but may shorten the regrowth timeline by stimulating anagen re-entry.

Oral low-dose minoxidil (0.25-1.25 mg daily in women, 2.5-5 mg daily in men) has emerging evidence for telogen effluvium and has been used off-label when topical compliance is poor 12.

Nutritional Supplementation

A 2023 systematic review in Skin Appendage Disorders found that combined iron, zinc, and biotin supplementation shortened telogen effluvium duration in nutritionally deficient patients by a mean of 6 weeks compared to iron alone 13. Biotin at 2.5-5 mg daily is safe and inexpensive; high-dose biotin (above 5 mg) can interfere with troponin and thyroid immunoassays and should be disclosed to any ordering clinician.

Skin Tightening Considerations

For patients concerned about skin laxity after retatrutide-induced weight loss, resistance training initiated early in the weight-loss process can preserve lean mass and maintain some structural support to the overlying skin 14. A resistance program of at least three sessions per week, targeting all major muscle groups, is consistent with current ACSM recommendations for weight-loss patients.

Non-invasive radiofrequency and high-intensity focused ultrasound (HIFU) devices have modest evidence for skin tightening in post-bariatric patients 15. These are adjuncts, not substitutes, for the primary preventive strategy of slowing the rate of weight loss through dose titration if laxity is a significant concern.

What Prescribers Should Tell Patients Before Starting Retatrutide

The following framework is used by the HealthRX clinical team when counseling patients who are beginning retatrutide therapy, either in a clinical trial or through off-label access.

Before the first dose:

• Set the expectation that diffuse hair shedding starting at weeks 8-14 is probable, not a sign of a drug reaction requiring discontinuation.
• Obtain baseline ferritin, TSH, zinc, and 25-OH vitamin D.
• Calculate a protein target (1.2-1.6 g/kg/day) and confirm the patient understands how to track intake.
• Document current skin quality and any pre-existing dermatologic conditions.

At week 12:

• Reassess ferritin and zinc. Begin supplementation if levels are suboptimal.
• Ask specifically about hair shedding volume. Clinicians who do not ask will not hear about it until it becomes severe.
• Review protein intake logs. Most patients are under-eating protein by this point.

At week 24:

• Reassess all nutritional labs.
• If shedding has not slowed and weight loss has reached or exceeded 15% of baseline, consider a temporary dose hold or reduction to slow the rate of loss without reversing it.
• Photograph hairline and vertex density for objective comparison at week 48.

At weight stability (typically week 36-52):

• Reassure the patient that telogen effluvium is expected to resolve within 3-6 months of stable weight.
• Continue protein targets and micronutrient supplementation until full regrowth is confirmed.

As Dr. Ania Jastreboff noted regarding the phase 2 findings, the adverse event profile of retatrutide was "generally consistent with GLP-1 receptor agonist class effects," with gastrointestinal events most common and alopecia among the notable secondary effects requiring patient counseling 1.

Ongoing Phase 3 Data and What to Expect

Phase 3 trials for retatrutide are underway as of mid-2025, with sample sizes substantially larger than the 338-person phase 2 cohort. Phase 3 datasets will allow more precise alopecia incidence estimates across subgroups including age, sex, baseline BMI, and concomitant medication use.

Given that SURMOUNT-1 for tirzepatide showed alopecia rates climbing from 5.7% at 15 mg in a 2,539-person population 4, retatrutide's larger efficacy signal suggests phase 3 alopecia rates may land in the 10-15% range at the highest approved doses. That remains a manageable, reversible adverse event when identified and addressed early.

The FDA typically requires class-effect labeling for alopecia on GLP-1-containing products. Retatrutide's label, when approved, will almost certainly include alopecia as a listed adverse reaction.